ABSTRACT
Two libraries of hMC4R agonists, X-Y-DPhe(7)-Arg(8)-2-Nal(9)-Z-NH(2) and X-Y-DPhe(7)-Arg(8)-Trp(9)-Z-NH(2), totaling 185 peptides were prepared using Irori radiofrequency tagging technology and Argonaut Quest 210 Synthesizer, where X stands for N-caps, Y for His(6) surrogates and Z for Gly(10) surrogates. As a result of this study, His-modified pentapeptides with Trp were found to be more hMC4R potent than the corresponding 2-Nal analogs, novel N-caps and Gly surrogates were identified and 19 new peptides which are potent hMC4R agonists (EC(50) 1-15nM) and selective against hMC1R were discovered.
Subject(s)
Oligopeptides/chemical synthesis , Peptide Library , Receptor, Melanocortin, Type 4/agonists , Amino Acid Sequence , Glycine , Humans , Oligopeptides/chemistry , Oligopeptides/pharmacology , Structure-Activity RelationshipABSTRACT
Linear pentapeptides (Penta-cis-Apc-DPhe-Arg-Trp-Gly-NH2) containing 1-amino-4-phenylcyclohexane-1-carboxylic acid (cis-Apc) and substituted Apc are potent hMC4R agonists and they are inactive or weakly active in hMC1R, hMC3R, and hMC5R agonist assays. This study, together with our earlier report on 5-BrAtc, demonstrated the importance of replacing His6 with phenyl-containing rigid templates in achieving good hMC4R agonist potency and selectivity against hMC1R in linear pentapeptides.
Subject(s)
Carboxylic Acids/chemistry , Carboxylic Acids/pharmacology , Cyclohexanes/chemistry , Cyclohexanes/pharmacology , Receptor, Melanocortin, Type 1/agonists , Receptor, Melanocortin, Type 4/agonists , Amino Acid Sequence , Humans , Inhibitory Concentration 50 , Molecular Structure , Sensitivity and Specificity , Substrate SpecificityABSTRACT
Using nuclear magnetic resonance (NMR) spectroscopy, we have determined the solution structures for a series of potent agonists for the human melanocortin-4 receptor (hMC4R), based on the cyclic peptide MT-II [Ac-Nle-cyclo-(Asp-Lys) (Asp-His-(D)Phe-Arg-Trp-Lys)-NH2]. Members of this series were designed to improve selectivity for MC4R versus the other melanocortin receptors, and to reduce the flexibility of the side chains. The most selective and rigid analog [penta-cyclo(D-K)-Asp-Apc-(D)Phe-Arg-(2S,3S)-beta-methylTrp-Lys-NH2] was found to be a full agonist of hMC4R with an EC50 of 11nM against hMC4R, and to exhibit 65-fold selectivity against hMC1R. This compound represents the most constrained hMC4R peptide agonist described to date. A beta-turn structure was conserved among all of the cyclic peptides studied. The rigidity of the analogs allowed an exceptionally well-defined pharmacophore model to be derived. This model was used to perform a virtual screen using a library of 1000 drug-like compounds, to which a small set of known potent ligands had been intentionally added. The utility of the model was validated by its ability to identify the known ligands from among this large library.
Subject(s)
Models, Molecular , Peptides, Cyclic/chemistry , Peptides, Cyclic/pharmacology , Receptor, Melanocortin, Type 4/agonists , Humans , Magnetic Resonance Spectroscopy , Molecular Conformation , Molecular Structure , Peptides, Cyclic/chemical synthesis , Protein Binding , Solutions , Structure-Activity RelationshipABSTRACT
A series of pentapeptides, based on hMC4R pentapeptide agonist (Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2)), was prepared in which either DPhe(7) or Trp(9) residue was systematically substituted. A number of interesting DPhe surrogates (D-Thi, D-3-CF(3)Phe, D-2-Nal and D-3,4-diClPhe) as well as Trp surrogates (2-Nal and Bta) were identified in this study.
Subject(s)
Oligopeptides/pharmacology , Receptor, Melanocortin, Type 4/agonists , Receptors, Melanocortin/agonists , Amino Acid Substitution , Cell Line , Humans , Obesity/drug therapy , Oligopeptides/chemistry , Receptor, Melanocortin, Type 4/genetics , Receptors, Melanocortin/genetics , Structure-Activity Relationship , TransfectionABSTRACT
A series of MT-II related cyclic peptides, based on potent but non-selective hMC4R agonist (Penta-c[Asp-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys]-NH(2)) was prepared in which His(6) residue was systematically substituted. Two of the most interesting peptides identified in this study are Penta-c[Asp-5-ClAtc-DPhe-Arg-Trp-Lys]-NH(2) and Penta-c[Asp-5-ClAtc-DPhe-Cit-Trp-Lys]-NH(2) which are potent hMC4R agonists and are either inactive or weak partial agonists (not tested for their antagonist activities) in hMC1R, hMC3R and hMC5R agonist assays.
Subject(s)
Histidine/chemistry , Receptors, Corticotropin/agonists , Amino Acid Substitution , Cell Survival/drug effects , Humans , Magnetic Resonance Spectroscopy , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/pharmacology , Receptor, Melanocortin, Type 4 , Receptors, Melanocortin , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Systematic substitution of His(6) residue using non-selective hMC4R pentapeptide agonist (Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2)) as the template led to the identification of Bu-Atc(6)(2-aminotetraline-2-carboxylic acid)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) which showed moderate selectivity towards hMC4R over hMC1R. Further SAR studies resulted in the discovery of Penta-5-BrAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) and Penta-5-Me(2)NAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) which are potent hMC4R agonists and are inactive in hMC1R, hMC3R and hMC5R agonist assays.
Subject(s)
Oligopeptides/chemical synthesis , Receptors, Corticotropin/agonists , Amino Acid Sequence , Amino Acid Substitution , Cyclic AMP/biosynthesis , Histidine , Humans , Oligopeptides/metabolism , Oligopeptides/pharmacology , Protein Binding , Receptor, Melanocortin, Type 4 , Receptors, Corticotropin/metabolism , Receptors, Melanocortin , Structure-Activity RelationshipABSTRACT
A series of pentapeptides, based on Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) and modified at the Arg(8) position, was prepared and pharmacologically characterized. Peptides containing either cyanoguanidine or acylguanidine, two substantially less basic arginine surrogates, were found to retain the agonist activity of the parent peptide at both hMC1R and hMC4R. This study unequivocally shows that the positive charge of Arg(8) is not essential for efficient interactions of our pentapeptide with both hMC1R and hMC4R.
